Back to Search Start Over

Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.

Authors :
Vitale A
Svegliati-Baroni G
Ortolani A
Cucco M
Dalla Riva GV
Giannini EG
Piscaglia F
Rapaccini G
Di Marco M
Caturelli E
Zoli M
Sacco R
Cabibbo G
Marra F
Mega A
Morisco F
Gasbarrini A
Foschi FG
Missale G
Masotto A
Nardone G
Raimondo G
Azzaroli F
Vidili G
Oliveri F
Pelizzaro F
Ramirez Morales R
Cillo U
Trevisani F
Miele L
Marchesini G
Farinati F
Source :
Gut [Gut] 2023 Jan; Vol. 72 (1), pp. 141-152. Date of Electronic Publication: 2021 Dec 21.
Publication Year :
2023

Abstract

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.<br />Methods: We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.<br />Results: MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006).<br />Conclusions: The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.<br />Competing Interests: Competing interests: None declared.<br /> (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
1468-3288
Volume :
72
Issue :
1
Database :
MEDLINE
Journal :
Gut
Publication Type :
Academic Journal
Accession number :
34933916
Full Text :
https://doi.org/10.1136/gutjnl-2021-324915